Zynerba Pharmaceuticals (NASDAQ:ZYNE) Trading 7.1% Higher …

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)’s share price traded up 7.1% on Tuesday . The company traded as high as $5.45 and last traded at $4.96, 2,076,982 shares traded hands during mid-day trading. An increase of 238% from the average session volume of 613,710 shares. The stock had previously closed at $4.63.

A number of research analysts recently weighed in on the stock. Roth Capital assumed coverage on shares of Zynerba Pharmaceuticals in a research note on Tuesday, December 31st. They issued a “buy” rating and a $12.00 price objective for the company. ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Thursday, February 20th. Finally, Zacks Investment Research downgraded shares of Zynerba Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $16.29.

The business’s 50-day simple moving average is $5.18 and its 200-day simple moving average is $7.29. The stock has a market cap of $105.33 million, a PE ratio of -2.87 and a beta of 4.59.

A number of institutional investors and hedge funds have recently made changes to their positions in ZYNE. Morgan Stanley grew its holdings in Zynerba Pharmaceuticals by 25.8% in the second quarter. Morgan Stanley now owns 128,769 shares of the company’s stock worth $1,745,000 after purchasing an additional 26,390 shares during the period. Commonwealth Equity Services LLC grew its stake in Zynerba Pharmaceuticals by 34.1% during the third quarter. Commonwealth Equity Services LLC now owns 18,092 shares of the company’s stock valued at $136,000 after acquiring an additional 4,600 shares in the last quarter. SG Americas Securities LLC grew its stake in Zynerba Pharmaceuticals by 174.4% during the third quarter. SG Americas Securities LLC now owns 42,463 shares of the company’s stock valued at $321,000 after acquiring an additional 26,990 shares in the last quarter. State Street Corp grew its stake in Zynerba Pharmaceuticals by 8.9% during the third quarter. State Street Corp now owns 383,997 shares of the company’s stock valued at $2,903,000 after acquiring an additional 31,345 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Zynerba Pharmaceuticals during the third quarter valued at $170,000. Institutional investors and hedge funds own 46.32% of the company’s stock.

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder.

See Also: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Zynerba Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

All copyrights for this article are reserved to This Publisher